*Review* **Recent Advances in Nanomedicine for the Diagnosis and Therapy of Liver Fibrosis**

**Xue Bai 1,2, Gaoxing Su 3,\* and Shumei Zhai 1,\***


Received: 31 August 2020; Accepted: 27 September 2020; Published: 29 September 2020

**Abstract:** Liver fibrosis, a reversible pathological process of inflammation and fiber deposition caused by chronic liver injury and can cause severe health complications, including liver failure, liver cirrhosis, and liver cancer. Traditional diagnostic methods and drug-based therapy have several limitations, such as lack of precision and inadequate therapeutic efficiency. As a medical application of nanotechnology, nanomedicine exhibits great potential for liver fibrosis diagnosis and therapy. Nanomedicine enhances imaging contrast and improves tissue penetration and cellular internalization; it simultaneously achieves targeted drug delivery, combined therapy, as well as diagnosis and therapy (i.e., theranostics). In this review, recent designs and development efforts of nanomedicine systems for the diagnosis, therapy, and theranostics of liver fibrosis are introduced. Relative to traditional methods, these nanomedicine systems generally demonstrate significant improvement in liver fibrosis treatment. Perspectives and challenges related to these nanomedicine systems translated from laboratory to clinical use are also discussed.

**Keywords:** nanomedicine; liver fibrosis; diagnosis; therapy; theranostics; targeted drug delivery
